Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study The Lancet Regional Health – AmericasPublished: February 9, 2024
No hay comentarios:
Publicar un comentario